Hepion Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Edison NJ United States (2013)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02322957
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ContraVir Pharmaceutical, Inc. | ContraVir Pharmaceuticals | ContraVir Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

fv-100 (2 trials)

valaciclovir (Valtrex) (1 trial)

Drugs in Phase 2 Trials (2)

tenofovir (viread) (4 trials)

Tenofovir exalidex (2 trials)

Drugs in Phase 1 Trials (1)

crv431 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Herpes Zoster (Phase 3)

Infections (Phase 2)

Liver Diseases (Phase 1)

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5